tradingkey.logo


Mirum Pharmaceuticals Inc

MIRM
79.833USD
-0.917-1.14%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
4.10BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc āļšāļĢāļīāļĐāļąāļ—

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

āļ‚āđ‰āļ­āļĄāļđāļĨ Mirum Pharmaceuticals Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MIRM
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Mirum Pharmaceuticals Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJul 18, 2019
āļ‹āļĩāļ­āļĩāđ‚āļ­Peetz (Christopher)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™322
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Jul 18
āļ—āļĩāđˆāļ­āļĒāļđāđˆ989 East Hillsdale Boulevard, Suite 300
āđ€āļĄāļ·āļ­āļ‡FOSTER CITY
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ94404
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ16506674085
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://mirumpharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MIRM
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJul 18, 2019
āļ‹āļĩāļ­āļĩāđ‚āļ­Peetz (Christopher)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
366.34K
+5.51%
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
--
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
39.66K
+28.33%
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Director
Independent Director
5.70K
--
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
5.65K
--
Mr. Andrew Mckibben
Mr. Andrew Mckibben
Investor Relations
Investor Relations
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
366.34K
+5.51%
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
--
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
39.66K
+28.33%
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Livmarli
88.16M
68.99%
Bile Acid Medicines
39.63M
31.01%
License and other revenue
0.00
0.00%
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Livmarli
88.16M
68.99%
Bile Acid Medicines
39.63M
31.01%
License and other revenue
0.00
0.00%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 19 āļž.āļĒ.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 19 āļž.āļĒ.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Frazier Life Sciences Management, L.P.
13.15%
Janus Henderson Investors
9.67%
BlackRock Institutional Trust Company, N.A.
5.87%
The Vanguard Group, Inc.
4.91%
Eventide Asset Management, LLC
4.88%
āļ­āļ·āđˆāļ™ āđ†
61.53%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Frazier Life Sciences Management, L.P.
13.15%
Janus Henderson Investors
9.67%
BlackRock Institutional Trust Company, N.A.
5.87%
The Vanguard Group, Inc.
4.91%
Eventide Asset Management, LLC
4.88%
āļ­āļ·āđˆāļ™ āđ†
61.53%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor/Hedge Fund
35.46%
Investment Advisor
34.76%
Hedge Fund
20.79%
Private Equity
13.59%
Research Firm
4.99%
Venture Capital
2.45%
Individual Investor
1.66%
Pension Fund
0.90%
Bank and Trust
0.25%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q3
468
57.20M
111.61%
-6.92M
2025Q2
458
58.36M
116.21%
-4.59M
2025Q1
454
57.59M
116.38%
-4.84M
2024Q4
425
56.60M
115.52%
-10.44M
2024Q3
408
56.58M
118.52%
-12.05M
2024Q2
398
57.22M
121.33%
-10.51M
2024Q1
391
57.27M
121.82%
-5.03M
2023Q4
376
54.05M
116.10%
-4.66M
2023Q3
337
55.34M
123.03%
+4.03M
2023Q2
315
43.67M
117.43%
-6.40M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Frazier Life Sciences Management, L.P.
6.80M
13.53%
--
--
Aug 18, 2025
Janus Henderson Investors
5.24M
10.42%
+154.32K
+3.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.10M
6.18%
+88.20K
+2.92%
Jun 30, 2025
The Vanguard Group, Inc.
2.56M
5.09%
+23.77K
+0.94%
Jun 30, 2025
Eventide Asset Management, LLC
2.64M
5.25%
+110.48K
+4.37%
Jun 30, 2025
BVF Partners L.P.
2.76M
5.5%
-35.18K
-1.26%
Jun 30, 2025
State Street Investment Management (US)
1.38M
2.74%
-118.94K
-7.96%
Jun 30, 2025
Novo Holdings A/S
1.50M
2.99%
+55.00
+0.00%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.38M
2.75%
-2.14K
-0.16%
Jun 30, 2025
Tang Capital Management, LLC
1.24M
2.46%
-1.08K
-0.09%
Jun 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 2 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 2 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Virtus LifeSci Biotech Products ETF
2.37%
Invesco Dorsey Wright Healthcare Momentum ETF
1.52%
ALPS Medical Breakthroughs ETF
1.51%
Federated Hermes MDT Small Cap Core ETF
1.14%
First Trust Innovation Leaders ETF
1.03%
Tema Heart & Health ETF
1.02%
First Trust Small Cap Growth AlphaDEX Fund
0.68%
State Street SPDR S&P Biotech ETF
0.58%
First Trust NASDAQ Pharmaceuticals ETF
0.52%
JPMorgan Fundamental Data Science Small Core ETF
0.43%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Virtus LifeSci Biotech Products ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.37%
Invesco Dorsey Wright Healthcare Momentum ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.52%
ALPS Medical Breakthroughs ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.51%
Federated Hermes MDT Small Cap Core ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.14%
First Trust Innovation Leaders ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.03%
Tema Heart & Health ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.02%
First Trust Small Cap Growth AlphaDEX Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.68%
State Street SPDR S&P Biotech ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.58%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.52%
JPMorgan Fundamental Data Science Small Core ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.43%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc āđ„āļ”āđ‰āđāļāđˆ:
Frazier Life Sciences Management, L.P. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 6.80M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 13.53% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Janus Henderson Investors āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 5.24M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 10.42% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
BlackRock Institutional Trust Company, N.A. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 3.10M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 6.18% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
The Vanguard Group, Inc. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 2.56M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 5.09% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Eventide Asset Management, LLC āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 2.64M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 5.25% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”

āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc āđ„āļ”āđ‰āđāļāđˆ
Frazier Life Sciences Management, L.P.
Janus Henderson Investors
BlackRock Institutional Trust Company, N.A.

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc (MIRM)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2025Q3 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 468 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 57.20M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 111.61% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q2 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ -4.60%

āđāļŦāļĨāđˆāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļ‚āļ­āļ‡ Mirum Pharmaceuticals Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āđ€āļĄāļ·āđˆāļ­āļ§āļąāļ™āļ—āļĩāđˆ FY2025Q2 āļ˜āļļāļĢāļāļīāļˆāļ”āđ‰āļēāļ™ Livmarli āļŠāļĢāđ‰āļēāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŠāļđāļ‡āļŠāļļāļ”āđƒāļŦāđ‰āļāļąāļš Mirum Pharmaceuticals Inc āļ„āļīāļ”āđ€āļ›āđ‡āļ™āļĄāļđāļĨāļ„āđˆāļē 88.16M āđāļĨāļ°āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 68.99% āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ
KeyAI
î™